In addition, isolation of tumor antigen–specific CD4+ Th cells directly ex vivo, on the basis of cell-surface characteristics, would increase their potential for use in combined CD4+/CD8+ adoptive T cell therapy approaches. Here, CD8A is linked to neoplasm.